Family Medicine | Page 100 of 374 | Links Medicus Content Curation & Alerts in Medicine

Recent updates to clinical practice guidelines for diabetes mellitus.

9 Mar, 2022 | 08:46h | UTC

Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus – Endocrinology and Metabolism

Association of acute respiratory failure in early childhood with long-term neurocognitive outcomes.

9 Mar, 2022 | 08:41h | UTC

Association of Acute Respiratory Failure in Early Childhood With Long-term Neurocognitive Outcomes – JAMA (link to abstract – $ for full-text)

Commentaries:

IQ Lower for Survivors of PICU Respiratory Failure Hospitalization – HealthDay

Investigating The Effects of Critical Illness in Early Childhood On Neurocognitive Outcomes – University of Pennsylvania School of Nursing

RCT: Combination treatment with Varenicline and Nicotine patch may increase smoking cessation rates among smokers who drink heavily.

9 Mar, 2022 | 08:44h | UTC

Effect of Combination Treatment With Varenicline and Nicotine Patch on Smoking Cessation Among Smokers Who Drink Heavily: A Randomized Clinical Trial – JAMA Network Open

Commentary: Combination treatment is effective for treating smokers who drink heavily – University of Chicago Medical Center

Commentary on Twitter

In this RCT, the combination of varenicline + nicotine patch was superior to placebo + nicotine patch in increasing smoking quit rates in smokers who drink heavily. https://t.co/UbekBdEjyA

— JAMA Network Open (@JAMANetworkOpen) March 4, 2022

Bisphosphonate nephropathy: A case series and review of the literature.

9 Mar, 2022 | 08:32h | UTC

Bisphosphonate nephropathy: A case series and review of the literature – British Journal of Clinical Pharmacology

Cross-sectional study: Objectively measured physical activity is inversely associated with nonalcoholic fatty liver disease.

9 Mar, 2022 | 08:24h | UTC

Objectively Measured Physical Activity Is Inversely Associated With Nonalcoholic Fatty Liver Disease: The Rotterdam Study – The American Journal of Gastroenterology

Commentary on Twitter

In the 📕#RedJournal:

Objectively Measured Physical Activity Is Inversely Associated with NAFLD: The Rotterdam Study
van Kleef, et al.

👉 https://t.co/Yk4o7Chj1q #gastroenterology #hepatology @trudyvoortman pic.twitter.com/BzPN7Et6jY

— AJG – The American Journal of Gastroenterology (@AmJGastro) February 26, 2022

RCT: Azithromycin is not effective for the prevention of recurrent wheeze following severe respiratory syncytial virus bronchiolitis.

8 Mar, 2022 | 08:49h | UTC

Azithromycin to Prevent Recurrent Wheeze Following Severe Respiratory Syncytial Virus Bronchiolitis – NEJM Evidence

Commentaries:

Study finds azithromycin use during RSV not useful in preventing recurrent wheezing, may cause harm – Vanderbilt University Medical Center

Antibiotic doesn’t prevent future wheezing in babies hospitalized with RSV – Washington University in St. Louis

Commentary on Twitter

This RCT tested oral azithromycin vs placebo to reduce recurrent wheeze (RW) in 1-18-month-olds hospitalized with acute severe RSV bronchiolitis. Azithromycin did not reduce occurrence of RW and may increase risk of RW in some groups. #AAAAI22 #Asthma #EBM https://t.co/jYcBuiQ8aY pic.twitter.com/u65NbQaIlX

— NEJM Evidence (@NEJMEvidence) February 28, 2022

Study shows the number of covid-19 infections missed by lateral flow tests “substantial enough to be of clinical importance”.

8 Mar, 2022 | 08:57h | UTC

News Release: Number of covid-19 infections missed by lateral flow tests “substantial enough to be of clinical importance,” warn experts – BMJ

Original Study: SARS-CoV-2 antigen lateral flow tests for detecting infectious people: linked data analysis – The BMJ

Commentaries:

Lateral flow tests may be missing ‘substantial’ number of COVID-19 infections – Imperial College London

Self-testing for asymptomatic non-contacts using rapid antigen tests—is this leading to a cost effective reduction in infection transmission? – The BMJ

RCT: Screening for atrial fibrillation in older adults using a single-lead ECG did not increase detection rates at one year.

8 Mar, 2022 | 09:51h | UTC

Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: the VITAL-AF Randomized Controlled Trial – Circulation (link to abstract – $ for full-text)

USPSTF Recommendation Statement: Still not enough evidence to recommend atrial fibrillation screening.

#ESCCongress – RCT: In individuals at risk for stroke, screening for atrial fibrillation using loop recorder resulted in a three-times increase in atrial fibrillation detection and anticoagulation initiation but did not reduce the risk of stroke or systemic arterial embolism.

#ESCCongress – RCT: Small benefit from systematic screening for atrial fibrillation in older adults – After a median follow-up of 6.9 y there were fewer events (stroke, embolism, bleeding, and death) in the intervention group (31·9%) vs. control group (33·0%).

Clinical Review: Screening and management of atrial fibrillation in primary care

Guidelines on management of persons with multimorbidity and polypharmacy.

8 Mar, 2022 | 08:41h | UTC

Italian guidelines on management of persons with multimorbidity and polypharmacy – Aging Clinical and Experimental Research

RCT: Little long-term benefit from a small change approach to prevent weight gain in adults with overweight and obesity.

8 Mar, 2022 | 08:37h | UTC

A small change approach to prevent long-term weight gain in adults with overweight and obesity: a randomized controlled trial – Canadian Medical Association Journal

Associations between alcohol consumption and gray and white matter volumes in the UK Biobank.

8 Mar, 2022 | 08:31h | UTC

Associations between alcohol consumption and gray and white matter volumes in the UK Biobank – Nature Communications

Commentaries:

More alcohol, less brain: Association begins with an average of just one drink a day – University of Pennsylvania

Just one drink per day can shrink your brain, study says – CNN

Study suggests switching among different generic levothyroxine products is not associated with clinically significant changes in TSH level.

8 Mar, 2022 | 08:30h | UTC

Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US Adults – JAMA Internal Medicine (link to abstract – $ for full-text)

Commentary: Generic Levothyroxine Switching and Thyrotropin Levels – American College of Cardiology

Review articles: Cutaneous manifestations of SARS-CoV-2 infection.

7 Mar, 2022 | 00:38h | UTC

Cutaneous Manifestations of SARS-CoV-2 Infection – American Journal of Clinical Dermatology

Common skin signs of COVID-19 in adults: An update – Cleveland Clinic Journal of Medicine

New research finds breast cancer overdiagnosis not as common as previously thought.

7 Mar, 2022 | 00:36h | UTC

Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort – Annals of Internal Medicine (link to abstract – $ for full-text)

How often is breast cancer overdiagnosed? New research finds true cases far outweigh false alarms – STAT

Breast cancer overdiagnosis may not happen as frequently as previously thought – ACP Internist

WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections.

7 Mar, 2022 | 00:09h | UTC

WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections – World Journal of Emergency Surgery

Systematic Review: Routine vaginal examinations compared to other methods for assessing progress of labor to improve outcomes for women and babies at term.

6 Mar, 2022 | 23:44h | UTC

Routine vaginal examinations compared to other methods for assessing progress of labour to improve outcomes for women and babies at term – Cochrane Library

Summary: Routine vaginal examinations in labour – Cochrane Library

M-A: Bariatric surgery and cardiovascular disease.

6 Mar, 2022 | 23:34h | UTC

Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis – European Heart Journal

Updated WHO guidance conditionally recommends Molnupiravir for patients with non-severe covid-19 at highest risk of hospitalization.

4 Mar, 2022 | 09:57h | UTC

BMJ News Release: WHO recommends antiviral drug for patients with non-severe covid-19 at highest risk of hospital admission – BMJ

WHO News Release: WHO updates its treatment guidelines to include molnupiravir

See updated guidance: A living WHO guideline on drugs for covid-19 – BMJ

Editorial (just published): Molnupiravir’s authorisation was premature – The BMJ

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

M-A: Efficacy of covid-19 vaccines in immunocompromised patients.

4 Mar, 2022 | 10:01h | UTC

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis – The BMJ

News Release: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom

Commentary on Twitter

NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav

— The BMJ (@bmj_latest) March 3, 2022